Low dose ASA

Phase 3Small molecule

Boehringer Ingelheim

Low dose ASA is one of 30 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

Venous ThromboembolismPhase 2

Active, not recruiting

Competition

Competitive Landscape

78 competitors in Venous Thromboembolism

#DrugCompanyPhaseTrials

Pradaxa

Boehringer Ingelheim

Phase 3

4 2

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 3

Fragmin

Pfizer

Phase 2

9 4

Low-Molecular-Weight Heparin

Daiichi Sankyo

Phase 3

3 5

Unfractionated Heparin

GSK

Phase 3

3 6

REGN7508

Regeneron

Phase 3

1 7

BAY 987519

Bayer

Phase 3

1 8

Dabigatran Dose 2

Boehringer Ingelheim

Phase 3

8 9

YM150

Astellas

Phase 3

7 10

Du-176b

Daiichi Sankyo

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Adult

NCT04284397

Q1 2031

Phase 2Recruiting

Venous Thromboembolism

NCT06866964

Clinical

Trials by Indication[1]

Adult1 trial

Identification of Critical Thermal Environments for Aged Adults

Recruiting·PPenn State University·Phase 1·NCT04284397·190 enrolled

Venous Thromboembolism1 trial

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT06866964·35 enrolled

Headache1 trial

Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02183688·1,889 enrolled

Injury1 trial

PGD2 Formation in Vascular Injury

Terminated·UUniversity of Pennsylvania··NCT01001260·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Low dose ASA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low dose ASA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low dose ASA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

Low dose ASA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2031

Trials by Indication[1]

Adult1 trial

Venous Thromboembolism1 trial

Headache1 trial

Injury1 trial

References

Drug Info

Quick Facts

Related News